Skip to main content
. 2016 Nov 26;8(1):808–818. doi: 10.18632/oncotarget.13656

Figure 1. Characteristic and expression of cir-ZNF609 in HSCR.

Figure 1

(A) The sequence of cir-ZNF609 in circBase (upper part) was consistent with the result of Sanger sequencing (lower part). (B) The circular RNA was resistant to RNase R treatment in 293T cell lines and SH-SY5Y cell lines. (C) The expression of cir-ZNF609 in HSCR tissues (n = 80) and control tissues (n = 78). Cir-ZNF609 was significantly reduced in patient tissues compared with control tissues. D: Receiver Operating Characteristic (ROC) curve for the cir-ZNF609 to distinguish HSCR cases from controls.